{
    "2020-01-11": [
        [
            {
                "time": "",
                "original_text": "四季度业绩有望继续向好，板块有望逐步渐入佳境-医药行业2019年业绩前瞻",
                "features": {
                    "keywords": [
                        "四季度业绩",
                        "向好",
                        "医药行业",
                        "业绩前瞻"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "巨丰原创：2019年最牛的是科技股 2020年还可以牛下去吗？",
                "features": {
                    "keywords": [
                        "科技股",
                        "2019年",
                        "2020年",
                        "牛市"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "沪指稳守3000点春季攻势挺进纵深",
                "features": {
                    "keywords": [
                        "沪指",
                        "3000点",
                        "春季攻势",
                        "挺进纵深"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "生物药企Arcutis递交招股书，获恒瑞JAK抑制剂的海外授权",
                "features": {
                    "keywords": [
                        "生物药企",
                        "Arcutis",
                        "招股书",
                        "恒瑞",
                        "JAK抑制剂",
                        "海外授权"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}